Chordia Therapeutics Enhances Transparency with Earnings Transcript
Chordia Therapeutics Inc. (JP:190A) has released an update.
Chordia Therapeutics Inc. has released the transcript of its earnings briefing for the fiscal year ended August 2024, aiming to enhance transparency and investor understanding. The company is actively developing cancer therapies, with its lead candidate CTX-712 undergoing Phase 1/2 clinical trials in the US.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.